Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean amino oil and fennel?
Displaying drugs 526 - 550 of 14898 in total

Niraparib

Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Matched Description: … [L43277] Niraparib is selective towards PARP-1 and PARP-2. ... [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health …
Matched Categories: … niraparib and abiraterone ... Antineoplastic and Immunomodulating Agents …

Manidipine

Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.
Approved
Investigational
Matched Description: … It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages …
Matched Categories: … delapril and manidipine ... ACE Inhibitors and Calcium Channel Blockers ... Calcium-Regulating Hormones and Agents …

Indacaterol

Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Description: … It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. ... rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and ... It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011 …
Matched Categories: … indacaterol and mometasone ... indacaterol and glycopyrronium bromide ... indacaterol, glycopyrronium bromide and mometasone …

Acrivastine

Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia. Acrivastine is...
Approved
Matched Description: … Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever ... associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and …

Relebactam

Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to avibactam.[A181195,A181207] It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. It is currently available in a combination product which includes imipenem and cilastatin to treat complicated urinary tract infections (UTIs), pyelonephritis, and complicated...
Approved
Investigational
Matched Description: … [A181207] It is currently available in a combination product which includes [imipenem] and [cilastatin ... ] to treat complicated urinary tract infections (UTIs), pyelonephritis, and complicated intra-abdominal ... [label] It is considered to be a last-line treatment option and gained FDA approval as part of the combination …
Matched Categories: … imipenem, cilastatin and relebactam …

Fosaprepitant

Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Approved
Matched Description: … It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment …
Matched Categories: … Aprepitant and Prodrugs …

Nefopam

Nefopam is under investigation for the prevention of Cholecystitis and Post Anaesthetic Shivering. Nefopam has been investigated for the prevention of Kidney Transplantation.
Approved
Investigational
Matched Description: … Nefopam is under investigation for the prevention of Cholecystitis and Post Anaesthetic Shivering. …

Dacomitinib

Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Copanlisib

Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was granted accelerated...
Approved
Investigational
Matched Description: … , that exists in different isoforms and is often overexpressed in hematological malignancies. ... pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and ... PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Dapsone

A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of...
Approved
Investigational
Matched Categories: … dapsone and rifampicin ... dapsone, rifampicin and clofazimine …

Technetium Tc-99m disofenin

Technetium Tc-99m disofenin is a radiopharmaceutical agent used in hepatobiliary imaging for diagnostic purposes. It is well suited for both planar and single photon tomographic scintigraphy to quantitatively measure the function of liver, gallbladder and bile ducts and detect any anatomical changes in the hepatobliary system. It is available as...
Approved
Matched Description: … the function of liver, gallbladder and bile ducts and detect any anatomical changes in the hepatobliary ... It is well suited for both planar and single photon tomographic scintigraphy to quantitatively measure ... Technetium Tc-99m is a metastable nuclear isomer and disofenin is an iminodiacetic acid derivative with …
Matched Categories: … Indicators and Reagents ... Amino Acids, Peptides, and Proteins ... Hepatic and Reticulo Endothelial System …

Relugolix

Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Description: … in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and ... [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist ... [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... relugolix, estradiol and norethisterone …

Midodrine

An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension.
Approved
Matched Categories: … Adrenergic and Dopaminergic Agents …

Ropivacaine

Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Approved
Matched Description: … It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the …

Sotalol

Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening...
Approved
Matched Description: … injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm ... [L6334] A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous …
Matched Categories: … sotalol and thiazides ... Beta Blocking Agents and Thiazides ... sotalol and acetylsalicylic acid ... Beta Blocking Agents, Non-Selective, and Thiazides …

Eflornithine

Eflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis. Further research has also implicated ornithine decarboxylase in other conditions like facial hirsutism and cancer, especially when ornithine decarboxylase is highly upregulated in tumor cells.[A4112, A262834] Additionally, ornithine decarboxylase is activated by c-myc or...
Approved
Withdrawn
Matched Description: … [A262839] In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA ... Further research has also implicated ornithine decarboxylase in other conditions like facial hirsutism and ... under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and …
Matched Categories: … Skin and Mucous Membrane Agents ... Amino Acids, Peptides, and Proteins ... Agents Against Leishmaniasis and Trypanosomiasis ... Antineoplastic and Immunomodulating Agents ... Antiparasitic Products, Insecticides and Repellents …

Linagliptin

Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Description: … that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and linagliptin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Dofetilide

Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.
Approved
Investigational
Matched Description: … flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. ... Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration ( ... FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and …

Trichlormethiazide

A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
Approved
Vet approved
Matched Categories: … trichlormethiazide and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... trichlormethiazide and potassium-sparing agents ... Low-Ceiling Diuretics and Potassium-Sparing Agents …

Metipranolol

A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.
Approved
Matched Description: … A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. ... It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent. …
Matched Categories: … Beta Blocking Agents and Thiazides ... Antiglaucoma Preparations and Miotics ... metipranolol and thiazides, combinations ... Beta Blocking Agents, Non-Selective, and Thiazides …

Gadobutrol

Gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age. Due to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to other GBCA and thus requires a lesser...
Approved
Matched Description: … macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and ... properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to other GBCA and …

Bromperidol

Bromperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.
Approved
Investigational
Matched Description: … been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and …

Rimegepant

Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine ... L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and ... was subsequently approved by the European Commission in April 2022 for both the treatment and prevention …

Loxapine

An antipsychotic agent used in schizophrenia. [PubChem]
Approved
Matched Categories: … Diazepines, Oxazepines, Thiazepines and Oxepines …

Amikacin

Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.[FDA label] Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A. Amikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as...
Approved
Investigational
Vet approved
Matched Description: … of breath and the coughing up of blood. ... some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum)[L4680]. ... that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and …
Matched Categories: … cefepime and amikacin …
Displaying drugs 526 - 550 of 14898 in total